Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Appoints Two Scientists to New Research Positions


CAMBRIDGE, Mass.--Millen nium Pharmaceuticals here has announced two major scientific appointments. Michael Pavia will become the company's chief technology development officer, while Kazumi Shiosaki will be senior director of drug discovery.

Pavia was formerly vice-president of Cambridge Research with the Sphinx Pharmaceuticals division of Eli Lilly. He has a background of over 15 years in pharmaceutical research and discovery, including stints with Genesis Pharmaceuticals and Parke-Davis. In his new position he will head the organization dedicated to Millennium's technology development efforts in such areas as informatics, proteomics, process technologies, systems, transcriptional profiling, technology transfer, and technology acquisition. The company said his responsibilities will include "advancing the development and implementation of Millennium's integrated platform of genomic technologies for broad application in the life sciences arena."

Meanwhile, Shiosaki will lead Millennium's drug discovery group, taking responsibility for such areas as assay development, screening, drug source, and chemistry. With over 13 years of experience in pharmaceutical research and development, she most recently worked at Abbott Laboratories, serving as senior project leader and associate fellow of the Volwiler Society, Antiviral Research. In her new position Shiosaki will direct Millennium's efforts in drug discovery, high-throughput screening, and lead optimization.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.